Format

Send to

Choose Destination
Clin Breast Cancer. 2019 Mar 6. pii: S1526-8209(18)30783-3. doi: 10.1016/j.clbc.2019.02.010. [Epub ahead of print]

Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study.

Author information

1
Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
2
SWOG Statistical Center, Seattle, WA.
3
Pharmaceutical Science, St. Jude Children's Research Hospital, Memphis, TN.
4
Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
5
Division of Research, Kaiser Permanente Northern California, Oakland, CA.
6
University of Arkansas for Medical Sciences, Little Rock, AR.
7
Loyola University Chicago Stritch School of Medicine, Maywood, IL.
8
University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.
9
University of Texas Health Science Center at San Antonio, San Antonio, TX.
10
The Angeles Clinic and Research Institute, Santa Monica, CA.
11
Heartland NCORP, Missouri Baptist Medical Center, St. Louis, MO.
12
Baylor College of Medicine, Houston, TX.
13
University of Texas M.D. Anderson Cancer Center, Houston, TX.
14
Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY. Electronic address: song.yao@roswellpark.org.

Abstract

INTRODUCTION:

GATA3 is a critical transcription factor in maintaining the differentiated state of luminal mammary epithelial cells. We sought to determine the prognostic and predictive roles of GATA3 genotypes for breast cancer.

PATIENTS AND METHODS:

Twelve single nucleotide polymorphisms (SNPs) were genotyped in 2 breast cancer cohorts, including the SWOG S8897 trial where patients were treated with adjuvant chemotherapy (CAF [cyclophosphamide, doxorubicin, 5-fluorouracil] vs. CMF [cyclophosphamide, methotrexate, 5-fluorouracil]) or untreated, and the observational Pathways Study.

RESULTS:

In the S8897 trial, rs3802604 and rs568727 were associated with disease-free survival and overall survival in the treated group, regardless of chemotherapy regimen. The GG genotype of rs3802604 conferred poorer overall survival (adjusted hazard ratio, 2.45; 95% confidence interval, 1.48-4.05) and disease-free survival (adjusted hazard ratio, 1.95; 95% confidence interval, 1.27-2.99) compared with the AA genotype. Similar associations were found for rs568727. In contrast, no association with either SNP was found in the untreated group. Subgroup analyses indicated that these 2 SNPs more strongly influenced outcomes in the patients who also received tamoxifen. However, the associations in the subgroup with tamoxifen treatment were not replicated in the Pathways Study, possibly owing to substantial differences between the 2 patient cohorts, such as chemotherapy regimen and length of follow-up. Results from joint analyses across these 2 cohorts were marginally significant, driven by the results in S8897. Bioinformatic analyses support potential functional disruption of the GATA3 SNPs in breast tissue.

CONCLUSIONS:

The present study provides some evidence for the predictive value of GATA3 genotypes for breast cancer adjuvant therapies. Future replication studies in appropriate patient populations are warranted.

KEYWORDS:

Chemotherapy; Pharmacogenetics; Recurrence; SNPs; Survival

PMID:
30928413
DOI:
10.1016/j.clbc.2019.02.010

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center